Methods utilizing active vitamin D analogs for the treatment of
malignancy-associated hypercalcemia. Methods comprise the application of
an effective amount of a hypocalcemic vitamin D compound to alleviate
hypercalcemia, lower serum parathyroid hormone related protein (PTHrP)
levels.
